Brind.
  1. Several companies, including Guardant Health and Myriad Genetics, are competing in the liquid biopsy market.

BioMark Diagnostics Inc. is developing a high-accuracy liquid biopsy platform specifically for Non-Small Cell Lung Cancer (NSCLC).

1 report, 1 independent Updated Aug 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

BioMark Diagnostics Inc. is developing a high-accuracy liquid biopsy platform specifically for Non-Small Cell Lung Cancer (NSCLC).

Keep exploring

Part of

Several companies, including Guardant Health and Myriad Genetics, are competing in the liquid biopsy market. All 1 developments

Coverage

Newest first; wire copies grouped